In Re: Valsartan Losartan and Irbesartan Products
| AUROBINDO PHARMA LTD, AUROBINDO PHARMA USA INC, AUROLIFE PHARMA LLC, MYLAN LABORATORIES LTD, MYLAN PHARMACEUTICALS INC and MYLAN NV |
| CONSUMER ECONOMIC LOSS PLAINTIFFS, THIRD-PARTY PAYOR PLAINTIFFS and MEDICAL MONITORING PLAINTIFFS |
| 23-8007 |
| February 22, 2023 |
| U.S. Court of Appeals, Third Circuit |
| Other |
Docket Report
RSS Track this Docket
This docket was last retrieved on February 24, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 2 CLERK ORDER Several defendants have filed four petitions for permission to appeal the districtFebruary 8, 2023, order regarding class certification. These petitions are consolidated so they will be considered together by a panel of this Court. It appears that class certification was sought by three groups of plaintiffs. To facilitate electronic filing for large groups of similarly situated parties represented by the same counsel, this Court's dockets will designate each group of plaintiffs as follows. Counsel is advised that these designated filers are for CM/ECF filing purposes only. Names of all represented parties must be listed on all forms, motions, and briefs. Any response(s) to these four petitions must be filed on or before March 9, 2023. Similarly situated parties are encouraged to file a single consolidated response addressing all petitions. The Court disfavors redundant submissions. If the Consumer Economic Loss Plaintiffs, Third-Party Payor Plaintiffs, or Medical Monitoring Plaintiffs want to respond to these petitions, a maximum of one response for each group may be filed. The pharmacies' petition at No. 23-8006 did not contain proof of service as required by Federal Rule of Appellate Procedure 25(d)(1)(a). Those petitioners must file a certification of service within three days of this order. The $500 fee paid by the NDEA petitioners for No. 23-8007 has been refunded. No fee is required unless this Court grants permission to appeal. [23-8008, 23-8005, 23-8006, 23-8007] (PDB) [Entered: 02/24/2023 02:04 PM] |
| Filing 1 Petition for Leave to Appeal pursuant to Fed. R. Civ. P. 23(f) filed by Petitioners Aurobindo Pharma Ltd, Aurobindo Pharma USA Inc, Aurolife Pharma LLC, Mylan NV, Mylan Pharmaceuticals Inc and Mylan laboratories Ltd. Received on 02/22/2023. Certificate of Service dated 02/22/2023. Service made by US mail. (PDB) [Entered: 02/24/2023 01:32 PM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
